Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Admilparant food effect study in healthy volunteers
NCT07225647Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of admilparant (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration at 13 days, Area Under the Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration at 13 days and 1 more. Started Nov 2025; status: completed.
02
Drugs
admilparant
Beyond the preview
Go deeper on NCT07225647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225647.